Alessandro Russo1,2, Ana Rita Lopes1,3, Michael G McCusker1, Sandra Gimenez Garrigues1, Giuseppina R Ricciardi2, Katherine E Arensmeyer1, Katherine A Scilla1, Ranee Mehra1, Christian Rolfo4. 1. Marlene and Stewart Greenebaum Comprehensive Cancer Center, University of Maryland School of Medicine, 22 S Greene Street Rm. N9E08, Baltimore, MD, 21201, USA. 2. Medical Oncology Unit, A.O. Papardo & Department of Human Pathology, University of Messina, Contrada Papardo, 98158, Messina, Italy. 3. Portuguese Institute of Oncology (IPO), Porto, Portugal. 4. Marlene and Stewart Greenebaum Comprehensive Cancer Center, University of Maryland School of Medicine, 22 S Greene Street Rm. N9E08, Baltimore, MD, 21201, USA. christian.rolfo@umm.edu.
Abstract
PURPOSE OF REVIEW: Over the last two decades, the identification of targetable oncogene drivers has revolutionized the therapeutic landscape of non-small cell lung cancer (NSCLC). The extraordinary progresses made in molecular biology prompted the identification of several rare molecularly defined subgroups. In this review, we will focus on the novel and emerging actionable oncogenic drivers in NSCLC. RECENT FINDINGS: Recently, novel oncogene drivers emerged as promising therapeutic targets besides the well-established EGFR mutations, and ALK/ROS1 rearrangements, considerably expanding the list of potential exploitable genetic aberrations. However, the therapeutic algorithm in these patients is far less defined. The identification of uncommon oncogene drivers is reshaping the diagnostic and therapeutic approach to NSCLC. The introduction of novel highly selective inhibitors is expanding the use of targeted therapies to rare and ultra-rare subsets of patients, further increasing the therapeutic armamentarium of advanced NSCLC.
PURPOSE OF REVIEW: Over the last two decades, the identification of targetable oncogene drivers has revolutionized the therapeutic landscape of non-small cell lung cancer (NSCLC). The extraordinary progresses made in molecular biology prompted the identification of several rare molecularly defined subgroups. In this review, we will focus on the novel and emerging actionable oncogenic drivers in NSCLC. RECENT FINDINGS: Recently, novel oncogene drivers emerged as promising therapeutic targets besides the well-established EGFR mutations, and ALK/ROS1 rearrangements, considerably expanding the list of potential exploitable genetic aberrations. However, the therapeutic algorithm in these patients is far less defined. The identification of uncommon oncogene drivers is reshaping the diagnostic and therapeutic approach to NSCLC. The introduction of novel highly selective inhibitors is expanding the use of targeted therapies to rare and ultra-rare subsets of patients, further increasing the therapeutic armamentarium of advanced NSCLC.
Authors: Lukas Bubendorf; Urania Dafni; Martin Schöbel; Stephen P Finn; Verena Tischler; Aleksandra Sejda; Antonio Marchetti; Erik Thunnissen; Eric K Verbeken; Arne Warth; Irene Sansano; Richard Cheney; Ernst Jan M Speel; Daisuke Nonaka; Kim Monkhorst; Henrik Hager; Miguel Martorell; Spasenija Savic; Keith M Kerr; Qiang Tan; Zoi Tsourti; Thomas R Geiger; Roswitha Kammler; Katja Schulze; Ashis Das-Gupta; David Shames; Solange Peters; Rolf A Stahel Journal: Lung Cancer Date: 2017-07-22 Impact factor: 5.705
Authors: Maria E Arcila; Jamie E Chaft; Khedoudja Nafa; Sinchita Roy-Chowdhuri; Christopher Lau; Michael Zaidinski; Paul K Paik; Maureen F Zakowski; Mark G Kris; Marc Ladanyi Journal: Clin Cancer Res Date: 2012-07-03 Impact factor: 12.531
Authors: U Gatzemeier; G Groth; C Butts; N Van Zandwijk; F Shepherd; A Ardizzoni; C Barton; P Ghahramani; V Hirsh Journal: Ann Oncol Date: 2004-01 Impact factor: 32.976
Authors: Zhan Yao; Rona Yaeger; Vanessa S Rodrik-Outmezguine; Anthony Tao; Neilawattie M Torres; Matthew T Chang; Matthias Drosten; Huiyong Zhao; Fabiola Cecchi; Todd Hembrough; Judith Michels; Hervé Baumert; Linde Miles; Naomi M Campbell; Elisa de Stanchina; David B Solit; Mariano Barbacid; Barry S Taylor; Neal Rosen Journal: Nature Date: 2017-08-02 Impact factor: 49.962
Authors: Suresh S Ramalingam; James C-H Yang; Chee Khoon Lee; Takayasu Kurata; Dong-Wan Kim; Thomas John; Naoyuki Nogami; Yuichiro Ohe; Helen Mann; Yuri Rukazenkov; Serban Ghiorghiu; Daniel Stetson; Aleksandra Markovets; J Carl Barrett; Kenneth S Thress; Pasi A Jänne Journal: J Clin Oncol Date: 2017-08-25 Impact factor: 44.544
Authors: J Mazieres; A Drilon; A Lusque; L Mhanna; A B Cortot; L Mezquita; A A Thai; C Mascaux; S Couraud; R Veillon; M Van den Heuvel; J Neal; N Peled; M Früh; T L Ng; V Gounant; S Popat; J Diebold; J Sabari; V W Zhu; S I Rothschild; P Bironzo; A Martinez-Marti; A Curioni-Fontecedro; R Rosell; M Lattuca-Truc; M Wiesweg; B Besse; B Solomon; F Barlesi; R D Schouten; H Wakelee; D R Camidge; G Zalcman; S Novello; S I Ou; J Milia; O Gautschi Journal: Ann Oncol Date: 2019-08-01 Impact factor: 32.976
Authors: Diego L Kaen; Nicolas Minatta; Alessandro Russo; Umberto Malapelle; Diego de Miguel-Pérez; Christian Rolfo Journal: Adv Exp Med Biol Date: 2021 Impact factor: 2.622
Authors: Anna Michelotti; Marco de Scordilli; Elisa Bertoli; Elisa De Carlo; Alessandro Del Conte; Alessandra Bearz Journal: Int J Mol Sci Date: 2022-06-17 Impact factor: 6.208
Authors: Alessandro Russo; Andrés F Cardona; Christian Caglevic; Paolo Manca; Alejandro Ruiz-Patiño; Oscar Arrieta; Christian Rolfo Journal: Transl Lung Cancer Res Date: 2020-12
Authors: Parneet K Cheema; Shantanu O Banerji; Normand Blais; Quincy S-C Chu; Patrice Desmeules; Rosalyn A Juergens; Natasha B Leighl; Brandon S Sheffield; Paul F Wheatley-Price; Barbara L Melosky Journal: Curr Oncol Date: 2021-11-09 Impact factor: 3.677